Document is current

Any future updates will be listed below

Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy

Crossref DOI link: https://doi.org/10.1007/s12185-022-03503-9

Published Online: 2022-12-04

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark